57
Views
21
CrossRef citations to date
0
Altmetric
Research Article

Experimental Model for Ophthalmopathy in BALB/c and Outbred (CD-1) Mice Genetically Immunized with G2s and the Thyrotropin Receptor

, , , &
Pages 403-413 | Published online: 07 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Claus H Nielsen, Daniel El Fassi, Hans C Hasselbalch, Klaus Bendtzen & Laszlo Hegedüs. (2007) B-cell depletion with rituximab in the treatment of autoimmune diseases. Expert Opinion on Biological Therapy 7:7, pages 1061-1078.
Read now
Junichi Tani, Bamini Gopinath, Bao Nguyen & Jack R Wall. (2007) Extraocular muscle autoimmunity and orbital fat inflammation in thyroid-associated ophthalmopathy. Expert Review of Clinical Immunology 3:3, pages 299-311.
Read now

Articles from other publishers (19)

Tanja Diana, Hans-Peter Holthoff, Julia Fassbender, Christian Wüster, Michael Kanitz, George J. Kahaly & Martin Ungerer. (2020) A Novel Long-Term Graves’ Disease Animal Model Confirmed by Functional Thyrotropin Receptor Antibodies. European Thyroid Journal 9:Suppl. 1, pages 51-58.
Crossref
Martin Ungerer, Julia Fa?bender, Zhongmin Li, G?tz M?nch & Hans-Peter Holthoff. (2016) Review of Mouse Models of Graves? Disease and Orbitopathy?Novel Treatment by Induction of Tolerance. Clinical Reviews in Allergy & Immunology 52:2, pages 182-193.
Crossref
J. P. Banga, S. Moshkelgosha, U. Berchner-Pfannschmidt & A. Eckstein. (2015) Modeling Graves’ Orbitopathy in Experimental Graves’ Disease. Hormone and Metabolic Research 47:10, pages 797-803.
Crossref
Mami Nakahara, Kristian Johnson, Anja Eckstein, Ryo Taguchi, Masanobu Yamada, Norio Abiru & Yuji Nagayama. (2012) Adoptive Transfer of Antithyrotropin Receptor (TSHR) Autoimmunity from TSHR Knockout Mice to Athymic Nude Mice. Endocrinology 153:4, pages 2034-2042.
Crossref
Shuang-Xia Zhao, Shanli Tsui, Anthony Cheung, Raymond S Douglas, Terry J Smith & J Paul Banga. (2011) Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA. Journal of Endocrinology 210:3, pages 369-377.
Crossref
Lisa M Esposito, Richard J Simpson, Kelley Strohacker, Katie C Carpenter & Brian K McFarlin. (2010) Defining a longitudinal survival model to examine forced treadmill running as a countermeasure for diet-induced weight gain. Laboratory Animals 44:4, pages 305-311.
Crossref
Leon Wescombe, Hooshang Lahooti, Bamini Gopinath & Jack R. Wall. (2009) The cardiac calsequestrin gene ( CASQ2 ) is up‐regulated in the thyroid in patients with Graves’ ophthalmopathy – support for a role of autoimmunity against calsequestrin as the triggering event . Clinical Endocrinology 73:4, pages 522-528.
Crossref
Naxin Guo, Carolyn J. Baglole, Charles W. O'Loughlin, Steven E. Feldon & Richard P. Phipps. (2010) Mast Cell-derived Prostaglandin D2 Controls Hyaluronan Synthesis in Human Orbital Fibroblasts via DP1 Activation. Journal of Biological Chemistry 285:21, pages 15794-15804.
Crossref
Selc¸uk Dağdelen, Yi-chi M. Kong & J. Paul Banga. (2009) Toward Better Models of Hyperthyroid Graves' Disease. Endocrinology and Metabolism Clinics of North America 38:2, pages 343-354.
Crossref
J. Paul BangaClaus H. NielsenJacqueline A. GilbertDaniel El FassiLaszlo Hegedus. (2008) Application of New Therapies in Graves' Disease and Thyroid-Associated Ophthalmopathy: Animal Models and Translation to Human Clinical Trials. Thyroid 18:9, pages 973-981.
Crossref
Simeon A. Lauer, Rona Z. Silkiss & Steven A. McCormick. (2008) Oral Montelukast and Cetirizine for Thyroid Eye Disease. Ophthalmic Plastic & Reconstructive Surgery 24:4, pages 257-261.
Crossref
Sandra M. McLachlanYuji Nagayama & Basil Rapoport. (2005) Insight into Graves’ Hyperthyroidism from Animal Models. Endocrine Reviews 26:6, pages 800-832.
Crossref
S. Kloprogge, L. Kowal, J. Wall & A.G. Frauman. (2018) The Clinicopathologic Basis of Graves' Ophthalmopathy: A Review. European Journal of Ophthalmology 15:3, pages 315-323.
Crossref
Michael Kazim. 2005. Orbital Disease. Orbital Disease 285 300 .
S. El-Kaissi, A. G. Frauman & J. R. Wall. (2004) Thyroid-associated ophthalmopathy: a practical guide to classification, natural history and management. Internal Medicine Journal 34:8, pages 482-491.
Crossref
Tsuyoshi Ohkura, Shin-ichi Taniguchi, Kazuhiro Yamada, Naoko Nishio, Tomohisa Okamura, Akio Yoshida, Keiichi Kamijou, Shuji Fukata, Kanji Kuma, Yoichi Inoue, Ichiro Hisatome, Satoru Senju, Yasuharu Nishimura & Chiaki Shigemasa. (2004) Detection of the novel autoantibody (anti-UACA antibody) in patients with Graves? disease. Biochemical and Biophysical Research Communications 321:2, pages 432-440.
Crossref
S. Y. Goh, S. C. Ho, L. L. Seah, K. S. Fong & D. H. C. Khoo. (2004) Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Graves' disease differ and suggest ophthalmopathy is a multiantigenic disease. Clinical Endocrinology 60:5, pages 600-607.
Crossref
T. Mizokami, M. Salvi & Jack R. Wall. (2014) Eye muscle antibodies in Graves’ ophthalmopathy: Pathogenic or secondary epiphenomenon?. Journal of Endocrinological Investigation 27:3, pages 221-229.
Crossref
J C FLYNN, P V RAO, M GORA, G ALSHARABI, W WEI, A A GIRALDO, C S DAVID, J P BANGA & Y M KONG. (2004) Graves’ hyperthyroidism and thyroiditis in HLA-DRB1*0301 (DR3) transgenic mice after immunization with thyrotropin receptor DNA. Clinical and Experimental Immunology 135:1, pages 35-40.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.